Combating castration-resistant prostate cancer by co-targeting the epigenetic regulators EZH2 and HDAC

While screening and early detection have reduced mortality from prostate cancer, castration-resistant disease (CRPC) is still incurable. Here, we report that combined EZH2/HDAC inhibitors potently kill CRPCs and cause dramatic tumor regression in aggressive human and mouse CRPC models. Notably, EZH2...

Descripción completa

Detalles Bibliográficos
Autores principales: Schade, Amy E., Kuzmickas, Ryan, Rodriguez, Carrie L., Mattioli, Kaia, Enos, Miriam, Gardner, Alycia, Cichowski, Karen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10138213/
https://www.ncbi.nlm.nih.gov/pubmed/37104245
http://dx.doi.org/10.1371/journal.pbio.3002038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10138213/
https://www.ncbi.nlm.nih.gov/pubmed/37104245
http://dx.doi.org/10.1371/journal.pbio.3002038

Ejemplares similares